Talaris Therapeutics is a late-clinical stage biotechnology company developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders.
TALS
1.78 as of 3/27/23
